From the FOREMOST study factors predicting progression from oligo to polyarticular PsA: Female sex, enthesitis and dactylitis found to increase the risk of progression. Among patients in FOREMOST receiving PBO, prior csDMARD use was protective. Abstract#0576 @RheumNow #ACR25 https://t.co/CFMhAFgFBa

Accdg to this retro analysis of their prospective cohort study from Toronto, 47 pts (10%) had D2M axSpA of whom 14 had tx-refractory dse. D2M pts - longer symptom duration; ⬆️ASDAS, BASDAI, BASMI, BASFI & ⬆️CRP 💡Consider non-dse factors in D2M pts #ACR25 @RheumNow Abs0547 https://t.co/MUUyyELbw8

#0191 We found that in a large South London RA cohort, use of advanced therapy in moderate disease (DAS28 3.2-5.1) generally followed NICE guidance. Gaps often reflected telehealth limiting DAS assessment and patient hesitancy. Self-assessment tools may help. @RheumNow #ACR25 https://t.co/UMGtkfABHn

Real-world T2T strategy from MONITOR-PsA cohort: 🎯 At 48 weeks - 33.6% (49/146) of pts achieved PASDAS 'moderate' response & 37% (54/146) achieved a 'good' response This was close to the T2T outcomes of the TICOPA trial Adapt a T2T approach in PsA tx #ACR25 @RheumNow Abs0572 https://t.co/FPiFIiO8Oe

Albach et al. CAR T-cells in D2T RA. 6 patients. Safety looks ok. ACR20 in 4/6, ACR50 in 2/6. ACPA and RF disappeared. Results maybe not as positive as we might have anticipated? @RheumNow #ACR25 Abstr#471 https://t.co/TaEVWiWsNm

SELECT-GCA (upadacitinib in GCA for 52w) we hoped it might have ongoing effect post-cessation Do we need to continue upa? Extension data (second year) flare survival curves are clear: continuing upa far outperforms placebo It seems >2y toci/upa for GCA #ACR25 ABST0776 @RheumNow https://t.co/uJA3uQyWxb

#0776 In the 2-yr SELECT-GCA trial, continued upadacitinib 15mg maintained remission in 69% vs 29% who switched to PBO, cutting flare risk by 90% and reducing steroid exposure by ~1g. No new safety signals in older adults (mean 71yrs). @RheumNow #ACR25 https://t.co/KC9sm3ic3q

Singla et al. In secukinumab phase 3 trials, fungal (inc candida) infections uncommon. 5.51 for sec vs 3.39 for PBO per 100PY. @RheumNow #ACR25 Abstr#585 https://t.co/g78zUsxD5a

Schmidt et al. 2 year results of SELECT-GCA, upadacitinib in GCA. Remission 69% if upa continued vs 29% if stopped. 90% lower risk of flare, 1G less steroid @RheumNow #ACR25 Abstr#0776 #ACRBest https://t.co/MgRo7kIgIw

Not all inflammatory nasal lesions are vasculitis! Dr. Zacharek presents from the ENT perspective @RheumNow #ACR25 https://t.co/TJ4d56oBaJ

Post-hoc PEXIVAS study, estimating risk of relapse from baseline variables Lotsa fancy stats, mostly corroborated known risk factors, but model predicted relapse reasonably well! Probably useful for approach to monitoring... mayyybe treatment? #ACR25 @RheumNow #Abstr0722 https://t.co/XI9y8KgDNR